This is a preview of subscription content, log in via an institution to check access.
References
Louis DN, Ohgaki H, Weistler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research, Lyon
Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-oncology 14(Sup 5):v33
Pouratian N, Schiff D (2010) Management of low-grade glioma. Curr Neurol Neurosci Rep 10:224–231
Appuzzo MLJ (1995) Benign cerebral glioma. American Association of Neurological Surgeons, Park Ridge
Schiff D (2011) Low-grade gliomas. J Neurosurg 115:945–947
Sanai N, Chang S, Berger MS (2011) Low-grade gliomas in adults. J Neurosurg 115:948–965
Merchant TE, Pollack IF, Loeffler JS (2010) Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol 20:58–66
Reames BN, Krell RW, Wong SL (2013) Critical evaluation of oncology clinical practice guidelines. J Clin Oncol 31:2563–2568
Institute of Medicine (2011) Clinical Practice Guidelines We Can Trust. National Academies Press, Washington, pp 1–300
Shaw EG, Wang M, Coons SW et al (2012) Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 30:3065–3070
NCI Press Release (2014) Adding chemotherapy following radiation treatment improves survival for adults with a slow-growing type of brain tumor. http://www.cancer.gov/newscenter/newsfromnci/2014/RTOG9802. Accessed date 3 Feb 2014
Buckner JC, Pugh SL, Shaw EG et al (2014) Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s suppl; abstr 2000
Buckner J, Shaw E, Pugh S et al (2014) R9802: Phase III study of radiation therapy with or without procarbazine, CCNU and vincristine (PCV) in low-grade glioma: results by histologic type. Neuro-Oncology 16(suppl 5):v11
Acknowledgments
We acknowledge the significant contributions of Laura Mitchell, Senior Manager Guidelines for the CNS, and also the AANS/CNS Joint Guidelines Committee for their review, comments and suggestions, as well as Anne Woznica and Mary Bodach for their assistance with the literature searches. We also acknowledge the following individual JGC members for their contributions throughout the review process: Kevin Cockroft, MD, Sepideh Amin-Hanjani, MD, Kimon Bekelis, MD, Isabelle Germano, MD, Daniel Hoh, MD, Steven Hwang, MD, Cheerag Dipakkumar Upadhyaya, MD, Christopher Winfree, MD, and Brad Zacharia, MD.
Conflict of interest
Low Grade Glioma Guidelines Task Force members were required to report all possible COIs prior to beginning work on the guideline, using the COI disclosure form of the AANS/CNS Joint Guidelines Committee, including potential COIs that are unrelated to the topic of the guideline. The CNS Guidelines Committee and Guideline Task Force Chair reviewed the disclosures and either approved or disapproved the nomination. The CNS Guidelines Committee and Guideline Task Force Chair may approve nominations of Task Force Members with possible conflicts and address this by restricting the writing and reviewing privileges of that person to topics unrelated to the possible COIs (Table 2).
Disclaimer of liability
The information in these guidelines reflects the current state of knowledge at the time of completion. Each section is designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient’s physician(s). If medical advice or assistance is required, the services of a competent physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.
Sources of support
These guidelines were funded exclusively by the CNS Guidelines Committee, with no funding from any outside commercial sources.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Olson, J.J., Kalkanis, S.N. & Ryken, T.C. Evidence-based clinical practice parameter guidelines for the treatment of adults with diffuse low grade glioma: introduction and methods. J Neurooncol 125, 449–456 (2015). https://doi.org/10.1007/s11060-015-1847-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-015-1847-5